Related Experiment Video
Updated: Jul 19, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Current and emerging treatment approaches for tobacco dependence
K Michael Cummings1, Martin Mahoney
1Department of Health Behavior, Roswell Park Cancer Institute,Elm and Carlton Streets, Buffalo, NY 14263, USA. Michael.cummings@roswellpark.org
Abstract:
Nicotine in tobacco is the primary reason why most people find it hard to stop using tobacco. Nicotine creates dependence by activating the dopaminergic reward system in the brain. Physiologic withdrawal symptoms that occur when nicotine is no longer administered reinforce continued nicotine administration to avoid withdrawal. Extrapolating from this evidence has led to the development of tobacco dependence pharmacotherapy based upon the concept of replacing and/or blocking the effects of nicotine in the brain. The efficacy of nicotine replacement and blockade treatments in lessening symptoms of nicotine withdrawal and increasing quit rates has been consistently demonstrated in clinical trials. Despite the availability of efficacious medications to treat nicotine dependence, current therapies remain underutilized across the population. Health-care providers need to systematically encourage all tobacco users to quit and ensure that their tobacco-using patients use evidence-based treatments when they attempt to quit.
Related Concept Videos
Drug Dependence
CNS Depressants: Alcohol and Nicotine
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
